GlassScriptPhysician profile
John Caldwell Moultrie
NPI 1417393893
$6,446.49
in general payments reported to CMS, 2019-2025
47 companies · $23.84 in 2025
The $23.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $530 · 2021: $1,396 · 2022: $1,691 · 2023: $2,216 · 2024: $306 · 2025: $23.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.63 | 2021-2025 | |
| Novo Nordisk INC | $688.12 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $441.39 | 2019-2023 | |
| Lilly USA, LLC | $404.81 | 2020-2023 | Mounjaro, Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $371.75 | 2020-2023 | Trintellix |
| Gilead Sciences, INC. | $305.71 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $242.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $203.78 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $193.33 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.59 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $180.91 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $147.92 | 2019-2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $140.88 | 2022-2023 | Quviviq |
| Abbott Laboratories | $134.29 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $132.24 | 2021-2023 | Farxiga, Breztri |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moultrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.